Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

NCT05663515 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05663515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05663515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
September 30, 2024
Completion date
October 1, 2026
Enrollment
24,000 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer